US FDA Greenlighting Dozens Of New Trials For Coronavirus Therapeutics
In less than three weeks, the number of clinical trials for potential treatments has jumped to 72, according to the FDA’s Coronavirus Treatment Acceleration Program.
You may also be interested in...
US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible
New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.
When A Sponsor Wants To Proceed On A COVID Product, US FDA Almost Never Says No
Bob Temple tells the Pink Sheet that many of the drugs that sponsors are bringing forward have “not much evidence” of antiviral properties, “but it's still worth trying.” Jacqueline Corrigan-Curay emphasizes that even as FDA responds to the enormous coronavirus challenge, the agency's other work continues.
US FDA Pushing Coronavirus Trial Sponsors To Include Control Groups
“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”